AR037586A1 - Antagonistas vii de los receptores ccr-3 - Google Patents
Antagonistas vii de los receptores ccr-3Info
- Publication number
- AR037586A1 AR037586A1 ARP020104583A ARP020104583A AR037586A1 AR 037586 A1 AR037586 A1 AR 037586A1 AR P020104583 A ARP020104583 A AR P020104583A AR P020104583 A ARP020104583 A AR P020104583A AR 037586 A1 AR037586 A1 AR 037586A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylamino
- cycloalkyl
- hydrogen
- halo
- Prior art date
Links
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 title abstract 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 23
- 125000000217 alkyl group Chemical group 0.000 abstract 17
- 229910052739 hydrogen Inorganic materials 0.000 abstract 15
- 239000001257 hydrogen Substances 0.000 abstract 15
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 13
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 9
- -1 halo C1-6 alkoxy Chemical group 0.000 abstract 9
- 125000002252 acyl group Chemical group 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000004442 acylamino group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000006413 ring segment Chemical group 0.000 abstract 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 102000004499 CCR3 Receptors Human genes 0.000 abstract 1
- 108010017316 CCR3 Receptors Proteins 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Los compuestos son útiles como antagonistas de los receptores CCR-3 y por lo tanto pueden ser usados para el tratamiento de las enfermedades mediadas por CCR-3. Son objetos secundarios de la presente solicitud: método de preparación de los compuestos, composición y uso para preparar medicamentos. Reivindicación 1: Un compuesto de fórmula (1) caracterizado porque: R1 es alquileno C1-2; R2 es fenilo opcionalmente sustituido; R3 es hidrógeno, alquilo C1-6, acilo, arilo o arilo-alquilo C1-6; el anillo A es cicloalquilo C3-7, heterociclilo, o fenilo opcionalmente sustituido; D es N o C-Rb; L es -C(=O)-, -C(=S)-, -SO2-, -C(=O)N(Ra)-, -C(=S)N(Ra)-, -SO2N(Ra)-, -C(=O)O-, -C(=S)O-, -S(=O)2O-; R4 es alquilo C1-6, cicloalquilo C3-7, alquenilo C2-6, alquinilo C2-6, heteroalquilo o acilo-alquilo C1-6; Ra es hidrógeno, alquilo C1-6, acilo, arilo, arilo-alquilo C1-6, alcoxicarbonilo C2-6 o benciloxicarbonilo; y Rb es hidrógeno o alquilo C1-6; y prodrogas, isómeros individuales, mezclas racémicas y no racémicas de isómeros y sales farmacéuticamente aceptables de los mismos; en donde: el término "fenilo opcionalmente sustituido" se refiere a un grupo fenilo que es opcionalmente sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en alquilo C1-6, halo-alquilo C1-6, hidroxi-alquilo C1-6, heteroalquilo, acilo, acilamino, amino, alquilamino C1-6, dialquilamino C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, -SO2NR'R'' (en donde R' y R'' son independientemente hidrógeno o alquilo C1-6), alcoxi C1-6, halo-alcoxi C1-6, alcoxicarbonilo C1-6, carbamoilo, hidroxi, halo, nitro, ciano, mercapto, metilenodioxi o etilenodioxi; el término "acilo" se refiere a un radical -C(O)R, en donde R es hidrógeno, alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-6, fenilo o fenilo-alquilo C1-6; el término "acilo-alquilo C1-6" se refiere a un radical -alquileno C1-6-C(O)R en donde R es hidrógeno, alquilo C1-6, halo-alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-6, fenilo opcionalmente sustituido, bencilo, hidroxi, alcoxi C1-6, amino, mono-alquilamino C1-6 o di-alquilamino C1-6; el término "arilo" se refiere a un radical hidrocarburo aromático monocíclico o bicíclico de 6 a 10 átomos del anillo que es opcionalmente sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en alquilo C1-6, halo-alquilo C1-6, hidroxi-alquilo C1-6, heteroalquilo, acilo, acilamino, amino, alquilamino C1-6, di-alquilamino C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, -SO2NR'R'' (en donde R' y R'' son independientemente hidrógeno o alquilo C1-6), alcoxi C1-6, halo-alcoxi C1-6, alcoxicarbonilo C1-6, carbamoilo, hidroxi, halo, nitro, ciano, mercapto, metilenodioxi o etilenodioxi; el término "heterociclilo" se refiere a un radical cíclico no aromático saturado o insaturado de 3 a 8 átomos del anillo en el cual uno o dos átomos del anillo son heteroátomos seleccionados entre NRx {en donde cada Rx es independientemente hidrógeno, alquilo C1-6, acilo, alquilsulfonilo C1-6, aminosulfonilo, (alquilamino C1-6)-sulfonilo, (di-alquilamino C1-6)-sulfonilo, carbamoilo, (alquilamino C1-6)-carbonilo, (di-alquilamino C1-6)-carbonilo, (carbamoil)-alquilo C1-6, (alquilamino C1-6)-carbonil-alquilo C1-6, o di-alquilaminocarbonilo C2-6-alquilo C1-6}, O, ó S(O)n (en donde n es un entero de 0 a 2), siendo los átomos restantes del anillo, C y pudiendo el anillo heterociclilo ser opcionalmente sustituido independientemente con uno, dos o tres sustituyentes seleccionados entre alquilo C1-6, halo-alquilo C1-6, heteroalquilo, halo, nitro, ciano-alquilo C1-6, hidroxi, alcoxi C1-6, amino, mono-alquilamino C1-6, di-alquilamino C1-6, arilo-alquilo C1-6, -(X)n-C(O)R (en donde X es O ó NR', n es 0 ó 1, R es hidrógeno, alquilo C1-6, halo-alquilo C1-6, hidroxi, alcoxi C1-6, amino, mono-alquilamino C1-6, di-alquilamino C1-6 o fenilo opcionalmente sustituido, y R' es hidrógeno o alquilo C1-6), -alquileno C1-6-C(O)R (en donde R es hidrógeno, alquilo C1-6, halo-alquilo C1-6, hidroxi, alcoxi C1-6, amino, mono-alquilamino C1-6, di-alquilamino C1-6 o fenilo opcionalmente sustituido) o -S(O)nRd (en donde n es un entero de 0 a 2, y Rd es hidrógeno (con la condición de que n sea 0), alquilo C1-6, halo-alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-6, amino, mono-alquilamino C1-6, di-alquilamino C1-6, o hidroxi-alquilo C1-6); el termino "heteroalquilo" se refiere a un radical alquilo en donde uno, dos o tres átomos de hidrógeno han sido reemplazados con un sustituyente seleccionado independientemente entre el grupo que consiste en -ORa, -NRbRc, y -S(O)nRd (en donde n es un entero de 0 a 2), entendiéndose que el punto de unión del radical heteroalquilo es a través de un átomo de carbono, en donde Ra es hidrógeno, acilo, alquilo C1-6, cicloalquilo C3-7 o cicloalquilo C3-7-alquilo C1-6; Rb y Rc son independientemente uno de otro hidrógeno, acilo, alquilo C1-6, cicloalquilo C3-7 o cicloalquilo C3-7-alquilo C1-6; cuando n es 0, Rd es hidrógeno, alquilo C1-6, cicloalquilo C3-7, o cicloalquilo C3-7-alquilo C1-6 y cuando n es 1 ó 2, Rd es alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-6, amino, acilamino, mono-alquilamino C1-6 o di-alquilamino C1-6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33481901P | 2001-11-30 | 2001-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037586A1 true AR037586A1 (es) | 2004-11-17 |
Family
ID=23308965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104583A AR037586A1 (es) | 2001-11-30 | 2002-11-28 | Antagonistas vii de los receptores ccr-3 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7019007B2 (es) |
| EP (1) | EP1453804B1 (es) |
| JP (1) | JP2005518364A (es) |
| KR (1) | KR100579352B1 (es) |
| CN (1) | CN1296356C (es) |
| AR (1) | AR037586A1 (es) |
| AT (1) | ATE370932T1 (es) |
| AU (1) | AU2002356694A1 (es) |
| BR (1) | BR0214611A (es) |
| CA (1) | CA2468402A1 (es) |
| DE (1) | DE60222015T2 (es) |
| ES (1) | ES2291539T3 (es) |
| MX (1) | MXPA04004980A (es) |
| PL (1) | PL373275A1 (es) |
| RU (1) | RU2004120065A (es) |
| WO (1) | WO2003045917A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02012712A (es) * | 2000-06-30 | 2003-04-25 | Bristol Myers Squibb Pharma Co | N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas. |
| EP1558599A4 (en) * | 2002-10-30 | 2007-06-27 | Merck & Co Inc | HETEROARYLPIPERIDINE MODULATORS DERCHEMOKIN RECEPTORACTIVITY |
| CA2515780C (en) * | 2003-02-20 | 2012-12-11 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| JP4384635B2 (ja) * | 2003-06-30 | 2009-12-16 | 住友化学株式会社 | 不斉尿素化合物およびこれを触媒として用いる不斉共役付加反応による不斉化合物の製造方法 |
| US7541468B2 (en) * | 2004-06-10 | 2009-06-02 | Bristol-Myers Squibb Company | Process of preparing N-ureidoalkyl-piperidines |
| BR112013006953A2 (pt) * | 2010-09-29 | 2016-07-26 | Intervet Int Bv | composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB953005A (en) * | 1961-02-24 | 1964-03-18 | Soc Ind Fab Antibiotiques Sifa | Substituted n-phenylethyl-n-phenyl-piperazines |
| US5051423A (en) | 1988-07-13 | 1991-09-24 | Schering Ag | Derivatized alkanolamines as cardiovascular agents |
| HU206337B (en) * | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
| JPH0592921A (ja) * | 1991-05-17 | 1993-04-16 | Yamanouchi Pharmaceut Co Ltd | シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤 |
| ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| GB9601724D0 (en) * | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
| ES2237850T3 (es) * | 1997-10-14 | 2005-08-01 | Mitsubishi Pharma Corporation | Compuestos de piperazina y su uso medicinal. |
| CA2347909A1 (en) | 1998-12-18 | 2000-06-22 | Joseph B. Santella, Iii | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| EP1156807A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
| AU2057200A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6331541B1 (en) * | 1998-12-18 | 2001-12-18 | Soo S. Ko | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| ATE302005T1 (de) * | 1998-12-18 | 2005-09-15 | Bristol Myers Squibb Pharma Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
| AU3126700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| EP1205473A4 (en) * | 1999-07-28 | 2004-06-16 | Daiichi Radioisotope Lab | VESAMICOL PIPERAZINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THESE DERIVATIVES |
| GB0012240D0 (en) * | 2000-05-19 | 2000-07-12 | Merck Sharp & Dohme | Therapeutic agents |
-
2002
- 2002-11-20 JP JP2003547369A patent/JP2005518364A/ja active Pending
- 2002-11-20 WO PCT/EP2002/012997 patent/WO2003045917A2/en not_active Ceased
- 2002-11-20 AT AT02803781T patent/ATE370932T1/de not_active IP Right Cessation
- 2002-11-20 DE DE60222015T patent/DE60222015T2/de not_active Expired - Fee Related
- 2002-11-20 PL PL02373275A patent/PL373275A1/xx not_active Application Discontinuation
- 2002-11-20 RU RU2004120065/04A patent/RU2004120065A/ru not_active Application Discontinuation
- 2002-11-20 AU AU2002356694A patent/AU2002356694A1/en not_active Abandoned
- 2002-11-20 CA CA002468402A patent/CA2468402A1/en not_active Abandoned
- 2002-11-20 ES ES02803781T patent/ES2291539T3/es not_active Expired - Lifetime
- 2002-11-20 BR BR0214611-8A patent/BR0214611A/pt not_active IP Right Cessation
- 2002-11-20 EP EP02803781A patent/EP1453804B1/en not_active Expired - Lifetime
- 2002-11-20 CN CNB028239768A patent/CN1296356C/zh not_active Expired - Fee Related
- 2002-11-20 MX MXPA04004980A patent/MXPA04004980A/es not_active Application Discontinuation
- 2002-11-20 KR KR1020047008306A patent/KR100579352B1/ko not_active Expired - Fee Related
- 2002-11-27 US US10/306,820 patent/US7019007B2/en not_active Expired - Fee Related
- 2002-11-28 AR ARP020104583A patent/AR037586A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1296356C (zh) | 2007-01-24 |
| ES2291539T3 (es) | 2008-03-01 |
| WO2003045917B1 (en) | 2003-12-04 |
| WO2003045917A3 (en) | 2003-10-09 |
| US20030153578A1 (en) | 2003-08-14 |
| EP1453804A2 (en) | 2004-09-08 |
| CN1599721A (zh) | 2005-03-23 |
| BR0214611A (pt) | 2004-09-14 |
| EP1453804B1 (en) | 2007-08-22 |
| KR20040062663A (ko) | 2004-07-07 |
| WO2003045917A2 (en) | 2003-06-05 |
| RU2004120065A (ru) | 2005-05-27 |
| US7019007B2 (en) | 2006-03-28 |
| CA2468402A1 (en) | 2003-06-05 |
| KR100579352B1 (ko) | 2006-05-12 |
| DE60222015T2 (de) | 2008-06-05 |
| ATE370932T1 (de) | 2007-09-15 |
| AU2002356694A1 (en) | 2003-06-10 |
| JP2005518364A (ja) | 2005-06-23 |
| DE60222015D1 (de) | 2007-10-04 |
| MXPA04004980A (es) | 2004-08-11 |
| PL373275A1 (en) | 2005-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032130A1 (es) | Un compuesto inhibidor de quinasas proteicas, una composicion farmaceutica que lo incluye, y un metodo para tratar afecciones con dicho compuesto | |
| ES2104708T3 (es) | Compuestos heterociclicos terapeuticos. | |
| PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
| MX9207335A (es) | Nuevos derivados del acido fosfonosuccinico, procesos para su preparacion y composicion farmaceuticas que los contiene. | |
| CR10145A (es) | Derivados de tropano útiles en terapia (divisional exp. 6800) | |
| PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| AR023659A1 (es) | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos | |
| AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
| UY28026A1 (es) | 4-piperazinilbencenosulfonilindoles y usos de los mismos. | |
| ECSP066667A (es) | Derivados de ciclohexano espirociclicos | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| BR0317294A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários | |
| UY28150A1 (es) | Agentes terapeuticos | |
| DOP2003000694A (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| BR0307406A (pt) | Indóis substituìdos como agonistas alfa-1 | |
| PL361361A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| AR029821A1 (es) | Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento | |
| UY29427A1 (es) | Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones | |
| NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| PE20221586A1 (es) | Derivados heterociclicos activos como plaguicidas con sustituyentes que contienen azufre | |
| AR037459A1 (es) | Antagonistas vi del receptor ccr-3 | |
| AR044518A1 (es) | Inhibidores de integrasa de hiv | |
| AR035451A1 (es) | Derivados de beta-carbolina, su uso para la fabricacion de un medicamento para el tratamiento de la depresion, ansiedad y desordenes bipolares, una composicion farmaceutica y una combinacion. | |
| SE0201658D0 (sv) | Immediate release pharmaceutical formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |